HIV transactivator of transcription enhances methamphetamine-induced Parkinson's-like behavior in the rats

NeuroReport

Volumn 25, Issue 11, 2014, Pages 860-864

  Liu, Zengxun ^a,b   Shi, Zhenchun ^b   Liu, Jintong ^a   Wang, Yang ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG MENTAL HEALTH CENTER   (China)

Author keywords

Methamphetamine; Striatum; Substantia nigra; Transactivator of transcription

Indexed keywords

DOPAMINE; INTERLEUKIN 1BETA; METHAMPHETAMINE; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANNULA; CORPUS STRIATUM; CYTOKINE PRODUCTION; DOPAMINE UPTAKE; DOPAMINERGIC TRANSMISSION; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; LOCOMOTION; MALE; MICROINJECTION; MOTOR PERFORMANCE; NEUROTOXICITY; NONHUMAN; OPEN FIELD TEST; PARKINSONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ROTAROD TEST; SUBSTANTIA NIGRA;

EID: 84926127716     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/WNR.0000000000000199     Document Type: Article

References (25)

1. Silverstein PS, Shah A, Gupte R, Liu X, Piepho RW, Kumar S, Kumar A. Methamphetamine toxicity and its implications during HIV-1 infection. J Neurovirol 2011;17:401-415.
2. Callaghan RC, Cunningham JK, Sykes J, Kish SJ. Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend 2012;120:35-40.
3. Ares-Santos S, Granado N, Moratalla R. The role of dopamine receptors in the neurotoxicity of methamphetamine. J Intern Med 2013;273:437-453.
4. Zou S, Fitting S, Hahn YK, Welch SP, El-Hage N, Hauser KF, Knapp PE. Morphine potentiates neurodegenerative effects of HIV-1 Tat through actions at mu-opioid receptor-expressing glia. Brain 2011;134:3616-3631.
5. Fitting S, Ignatowska-Jankowska BM, Bull C, Skoff RP, Lichtman AH, Wise LE, et al. Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice. Biol Psychiatry 2013;73:443-453.
6. Theodore S, Stolberg S, Cass WA, Maragos WF. Human immunodeficiency virus-1 protein Tat and methamphetamine interactions. Ann N Y Acad Sci 2006;1074:178-190.
7. Lessard A, Couture R. Modulation of cardiac activity by tachykinins in the rat substantia nigra. Br J Pharmacol 2001;134:1749-1759.
8. Yabuki Y, Ohizumi Y, Yokosuka A, Mimaki Y, Fukunaga K. Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice. Neuroscience 2014;259:126-141.
9. Marques MR, Stigger F, Segabinazi E, Augustin OA, Barbosa S, Piazza FV, et al. Beneficial effects of early environmental enrichment on motor development and spinal cord plasticity in a rat model of cerebral palsy. Behav Brain Res 2014;263:149-157.
10. Arndt DL, Arnold JC, Cain ME. The effects of mGluR2/3 activation on acute and repeated amphetamine-induced locomotor activity in differentially reared male rats. Exp Clin Psychopharmacol 2014 [Epub ahead of print].
11. Todd G, Noyes C, Flavel SC, Della Vedova CB, Spyropoulos P, Chatterton B, et al. Illicit stimulant use is associated with abnormal substantia nigra morphology in humans. PloS One 2013;8:e56438.
12. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J. Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res 1980;181:151-160.
13. Sonsalla PK, Jochnowitz ND, Zeevalk GD, Oostveen JA, Hall ED. Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res 1996;738:172-175.
14. Zhu JP, Xu W, Angulo N, Angulo JA. Methamphetamine-induced striatal apoptosis in the mouse brain: comparison of a binge to an acute bolus drug administration. Neurotoxicology 2006;27:131-136.
15. Ares-Santos S, Granado N, Espadas I, Martinez-Murillo R, Moratalla R. Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining. Neuropsychopharmacology 2014;39:1066-1080.
16. O'Callaghan JP, Miller DB. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 1994;270:741-751.
17. Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D. Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci 2002;22:8951-8960.
18. Ferris MJ, Frederick-Duus D, Fadel J, Mactutus CF, Booze RM. In vivo microdialysis in awake, freely moving rats demonstrates HIV-1 Tat-induced alterations in dopamine transmission. Synapse 2009;63:181-185.
19. Midde NM, Gomez AM, Zhu J. HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes. J Neuroimmune Pharmacol 2012;7:629-639.
20. Jin J, Lam L, Sadic E, Fernandez F, Tan J, Giunta B. HIV-1 Tat-induced microglial activation and neuronal damage is inhibited via CD45 modulation: a potential new treatment target for HAND. Am J Transl Res 2012;4:302-315.
21. Lu SM, Tremblay ME, King IL, Qi J, Reynolds HM, Marker DF, et al. HIV-1 Tat-induced microgliosis and synaptic damage via interactions between peripheral and central myeloid cells. PloS one 2011;6:e23915.
22. Conant K, St Hillaire C, Anderson C, Galey D, Wang J, Nath A. Human immunodeficiency virus type 1 Tat and methamphetamine affect the release and activation of matrix-degrading proteinases. J Neurovirol 2004;10:21-28.
23. Fitting S, Xu R, Bull C, Buch SK, El-Hage N, Nath A, et al. Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol 2010;177:1397-1410.
24. Cass WA, Harned ME, Peters LE, Nath A, Maragos WF. HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res 2003;984:133-142.
25. Theodore S, Cass WA, Nath A, Steiner J, Young K, Maragos WF. Inhibition of tumor necrosis factor-alpha signaling prevents human immunodeficiency virus-1 protein Tat and methamphetamine interaction. Neurobiol Dis 2006;23:663-668.